15.09.2015 • NewsDede WillamsMerck SeronoMerck

Merck Serono Expands Biopharmaceuticals Lab

Merck Serono, the biopharmaceutical arm of Germany’s Merck KGaA, has laid the cornerstone for a new €65 million laboratory at its Darmstadt headquarters. When completed in 2017, some 200 employees will work in the 16,000 m2 building designed to accelerate innovation in R&D.

The research building will unite various functions within R&D Discovery Technologies at Merck, including Molecular Pharmacology; Medicinal Chemistry; Computational Chemistry; Molecular Interactions and Biophysics; Protein Engineering and Antibody Technologies, along with Protein and Cell Sciences.

Over the next few years, “we are poised to deliver the innovation discovered in our own laboratories to patients in need around the world,” Belén Garijo, member of the Merck executive board and CEO of Healthcare, said at the cornerstone-laying ceremony.

The Germany-based group, which employs 2,000 scientific and clinical development professionals at its R&D hubs in Darmstadt, Boston, Massachusetts in the US, Tokyo, Japan, and Beijing, China. Core areas of focus at the four locations are oncology, immuno-oncolgy and immunology.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.